Article Information
History
- August 21, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Vincent C. Marconi1,*,
- Adrian Kilcoyne2,
- Franklin Cerasoli3,
- Christopher Polk4,
- Meghan Lewis5,
- Charles D. Burger6,
- Edward Jordan2,
- Cameron Durrant2,
- Dale Chappell2 and
- Zelalem Temesgen7
- 1Emory University School of Medicine and Rollins School of Public Health, Atlanta, GA, USA
- 2Humanigen Inc, Short Hills, New Jersey, USA
- 3RxMedical Dynamics, LLC, New York, NY, USA
- 4Department of Medicine, Atrium Health, Charlotte, NC, USA
- 5Keck School of Medicine, University of Southern California, Los Angeles, California, USA
- 6Mayo Clinic, Division of Pulmonary, Allergy and Sleep Medicine, Jacksonville, FL, USA
- 7Mayo Clinic, Division of Infectious Disease, Rochester, MN, USA
- ↵*Corresponding Author
Vincent C. Marconi, MD, Ponce De Leon Center, 341 Ponce De Leon Ave. NE, Atlanta, GA 30308, vcmarco{at}emory.edu
Posted August 21, 2022.
LENZILUMAB OUTCOMES ACCORDING TO RACE OF COVID-19 PARTICIPANTS IN THE LIVE-AIR PHASE 3 TRIAL
